All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

By the year 2050, approximately 1.5 billion people worldwide would be aged ≥65 years; nearly triple the number reported in 2010. This increase in the elderly population, accompanied by an increase in chronic diseases and polypharmacy, is a major global public health concern facing our generation \[[@pone.0169463.ref001]\]. In the Republic of Korea, the elderly (aged ≥65 years) will comprise more than one-third of the total population by 2050. Further, the proportion of patients with chronic diseases amongst the elderly population has increased from 85.5% in 2008 to 93.9% in 2011, and the average number of comorbidities per patient has increased from 2.7 to 4.2 \[[@pone.0169463.ref002]\]. These trends inevitably lead to both the overall rise in health care costs and declines in the health-related quality of life \[[@pone.0169463.ref003]\]. Dementia, due to its rapidly increasing incidence and a high economic burden as a result of the growing social care and direct treatment-related costs to the patients, is one of the chronic diseases whose management has received very high priority. By 2050, the number of people with dementia is expected to be more than triple of what it is today \[[@pone.0169463.ref004]\], and as of 2010, the worldwide dementia management cost is estimated at USD 604 billion, an amount likely to increase further in the future \[[@pone.0169463.ref005]\].

Increase in the number of elderly people, and in the incidence of chronic diseases are both linked to polypharmacy, which is defined by the world health organization as the administration of multiple drugs concurrently or an excessive number of drugs \[[@pone.0169463.ref006]\]. However, as the definition of polypharmacy does not specify the duration of administration and the number of drugs, most commonly used criterion is the administration of five or more drugs per day for a certain period of time \[[@pone.0169463.ref007]--[@pone.0169463.ref012]\]. Polypharmacy and incidence of chronic diseases have increased concomitantly. In the elderly, prolonged exposure to polypharmacy results in a vicious cycle wherein the treatment of chronic diseases results in polypharmacy, which in turn gives rise to new comorbidities requiring further medication \[[@pone.0169463.ref013], [@pone.0169463.ref014]\]. Furthermore, taking a number of drugs simultaneously may increase the risk of transient adverse drug reactions, and the patients' health outcomes may deteriorate irreversibly with extended periods of polypharmacy \[[@pone.0169463.ref015]--[@pone.0169463.ref018]\].

Previous studies have demonstrated that polypharmacy increases the risk of unfavorable health outcomes such as adverse drug reactions, falls, fall-related outcomes, increased frequency of hospitalization, and mortality \[[@pone.0169463.ref009], [@pone.0169463.ref011]\]. However, only a few studies have assessed the association between polypharmacy and dementia. Lau *et al*. studied the association between polypharmacy and potentially inappropriate medication (PIM) use in elderly people (≥65 years) with dementia using a 4-year observational dataset from the National Alzheimer\'s Coordinating Center in the United States. Their study noted that elderly people receiving five or more medications exhibited a higher tendency for PIM administration than those receiving less than five drugs \[[@pone.0169463.ref019]\]. In the study by Lai *et al*., polypharmacy, which they defined as the administration of five or more drugs, was observed at significantly higher frequency in the dementia-afflicted cases than in the controls (P\<0.00001). Moreover, they noted that the increasing number of drugs and age were both associated with the incidence of dementia \[[@pone.0169463.ref020]\]. However, the study by Lau *et al*. could not evaluate the causal relationship between dementia and polypharmacy due to the cross-sectional study design, and the study by Lai *et al*. did not consider the complex interactions between PIMs and/or comorbidities and polypharmacy. Therefore, this study aimed to analyze the association between polypharmacy and dementia in a large patient cohort database. We utilized a 12-year longitudinal cohort (2002--2013), representing the entire population of South Korea, to evaluate the association between polypharmacy and dementia, taking into account the interaction among PIMs and comorbidities. Our study results emphasize the need for effective management of polypharmacy and drug administration to reduce the risk of dementia in the elderly.

Methods {#sec002}
=======

Study database {#sec003}
--------------

The National Health Insurance Service-National Sample Cohort (NHIS-NSC) database (n = 1,025,340; 2002--2013) was used for this study. The South Korean NHIS system includes the entire national population (\~50 million people), and the database was established for claim reimbursements. The NHIS-NSC database was constructed by the NHIS for health-related research, and the data is openly accessible to researchers. For sampling, 756 strata based on some variables such as 18 groups for age, 21 groups for income level by insurance type (10 groups for NHIS district subscriber and 10 groups for NHIS employee subscriber, one group for medical aid), and sex was set up by using 2002 data. The sampled individuals were followed until 2013. As a semi-dynamic cohort, information on newborns was added to the NHIS-NSC database to supplement data points lost due to deaths \[[@pone.0169463.ref021]\]. Data on subject characteristics, clinical information, beneficiary's socioeconomic level, and death records were included in the database. Clinical information including disease diagnosis codes based on the International Codes of Disease 10^th^ Edition (ICD-10) Clinical Modification, treatments based on drug prescriptions, and health care costs were recorded.

Patient involvement {#sec004}
-------------------

Patients were not directly involved in the research, and only the secondary electronic database was used for the analysis. Informed consent was not required as the database maintained de-identification and anonymity of sampled individuals. This study was approved by the Kyungpook National University Institutional Review Board (KNU 2014--85--0).

Study design and selection of cases and controls {#sec005}
------------------------------------------------

A nested case-control design was applied to this study. Community-dwelling elderly patients aged ≥65 years with no prior hospitalization history were initially selected from the NHIS-NSC database. Cases were defined as community-dwelling elderly patients with dementia who utilized outpatient service more than once, who had no prior hospitalization history, and who were newly diagnosed with dementia from 2005 to 2013. Dementia was defined as the presence of more than one of the following ICD-10 codes: F00 (dementia in Alzheimer's disease), F01 (vascular dementia), F02 (dementia in other diseases classified elsewhere), F03 (unspecified dementia), F051 (delirium superimposed on dementia), G30 (Alzheimer's disease), and G311 (senile degeneration of the brain, not elsewhere classified). Controls were selected through a 1:1 matching to the cases based on age, sex, index of income level, and year of dementia diagnosis.

Polypharmacy prescription {#sec006}
-------------------------

The index date was set as the date of dementia diagnosis in a case, and the matched control had the same index date as the case. Drug prescription history was investigated for the look-back period, defined as the last 2 years from the index date. The number of average prescribed daily drugs were estimated by adding all drugs prescription days in the 2-year period and dividing the sum by 730, a formula based on a previous study by Lai *et al*. (average number of prescribed daily drugs = {\[(1 type of drug) × (days used)\] + \[(2 types of drug) × (days used)\] + \[(3 types of drug) × (days used)\] + \[(4 types of drug) × (days used)\] + \[(5 types of drug) × (days used) +... + \[(10 or more types of drug) × (days used)\]/730 days). In the case of a combination of drugs for hypertension or diabetes, the number of active ingredients were used for calculations instead of the number of drugs, and polypharmacy was defined as an average prescription of five or more drugs per day \[[@pone.0169463.ref020]\].

Comorbidities {#sec007}
-------------

The Charlson comorbidity index (CCI) diseases, and a range of comorbidities related to dementia, such as hypertension, depression, and psychiatric diseases, were compared between the cases and controls during the look-back period. The CCI scores were used as health status indices and were calculated according to the prevalence of CCI diseases \[[@pone.0169463.ref022]\]. All comorbidities were defined by the ICD-10 codes, and the list of diseases and the ICD-10 codes used for the analysis are summarized in [S1 Table](#pone.0169463.s001){ref-type="supplementary-material"}.

Potentially inappropriate medication (PIM) {#sec008}
------------------------------------------

Based on the 2015 American Geriatrics Society Beers Criteria, PIM for dementia includes benzodiazepines, anticholinergic drugs, and H2-receptor antagonists \[[@pone.0169463.ref023]\]. PIM use was thus defined as the prescription for benzodiazepines, anticholinergic drugs, and H2-receptor antagonists during the look-back period. PIM use was measured according to the medication procession ratio (MPR), which is defined for each specific PIM as the percentage of prescription days for the total observation period (i.e., 2 years for this study).

Statistical analysis {#sec009}
--------------------

The demographic and clinical characteristics of the study population were analyzed and described by average and standard deviation (SD) for numerical variables, and frequency and percentage were used for categorical variables. The association between the use of PIMs and the diagnosis of dementia was analyzed using a univariate logistic regression analysis. To estimate the association between polypharmacy and dementia, crude odds ratios (ORs) were calculated using univariate logistic regression analyses for total subjects and various subgroups. Subject subgroups were defined based on the type of dementia, or the presence/absence of comorbidities. Dementia patients were classified into three categories: patients with Alzheimer's disease with ICD-10 codes of F00 and G30, without F01, F02, F03, F051, G311; patients with other causes of dementia with ICD-10 codes of F01, F02, F03, F051, and G311, without ICD-10 codes of F00 or G30; and mixed dementia patients with Alzheimer's disease codes (F00 or G30) and any other causes of dementia codes (F01, F02, F03, F051, G311) simultaneously. The univariate logistics regression analyses for comorbidity-based patient subgroups were integrated by inverse variance and are presented as integrated ORs. Interactions between polypharmacy and comorbidities, or PIM, were tested, and multiple logistic regression analyses were performed to adjust for comorbidity status and PIM use with or without the inclusion of interactions between polypharmacy and comorbidities or PIMs.

Results {#sec010}
=======

The total number of community-dwelling outpatients aged ≥65 years, without any hospitalization history, was 39,013. Of them, a total of 5,562 individuals fulfilled the inclusion criteria for the cases and controls. The proportions of dementia subtypes with Alzheimer's disease, other causes, and mixed type of both Alzheimer's disease and other causes were 33.1% (n = 1,841), 38.5% (n = 2,139), and 28.4% (n = 1,582), respectively ([Fig 1](#pone.0169463.g001){ref-type="fig"}).

![Selection of cases and controls.\
^a^ Alzheimer's disease dementia: patients with ICD-10 codes of F00 and G30, without F01, F02, F03, F051, and G311. ^b^ Other cause dementia: patients with ICD-10 codes of F01, F02, F03, F051, and G311, without ICD-10 codes of F00 or G30 ^c^ Mixed dementia: patients with Alzheimer's disease codes (F00 or G30) and any other cause dementia codes (F01, F02,F03, F051, G311) simultaneously.](pone.0169463.g001){#pone.0169463.g001}

The study population comprised 71.8% women, and the average age of the population was 73.3 (SD: 6.9) years. Cases had 2.14-point higher CCI score compared to controls (3.65 versus 1.51). Comorbidities were more prevalent in the cases. The prevalence of cerebrovascular diseases, hemiplegia, depression, delirium, behavioral disorders due to alcohol, schizophrenia, and psychotic disorders were \>3-times higher in the cases than in controls. Hypertension was the most common comorbidity noted in both groups, and its prevalence was higher in the cases than in the controls (66.6% versus 48.6%). In general, the other cause dementia cases exhibited a higher prevalence of comorbidities than the Alzheimer's disease and mixed dementia cases ([S2 Table](#pone.0169463.s002){ref-type="supplementary-material"}). The average number of prescribed daily drugs during the look-back period was 2.54 (SD: 2.87) for the cases and 1.75 (SD: 2.39) for the controls. Thus, the subjects in the case group were administered 0.79 drugs more each day during the 2 years prior to dementia diagnosis, compared to the subjects in the control group ([Table 1](#pone.0169463.t001){ref-type="table"}).

10.1371/journal.pone.0169463.t001

###### Demographic and clinical information for cases and controls.

![](pone.0169463.t001){#pone.0169463.t001g}

  Number of subjects                                                                    Cases (n = 5,562)       Controls (n = 5,562)                       
  ------------------------------------------------------------------------------------- ----------------------- ---------------------- ---------- -------- ----------
  **Sex**[^a^](#t001fn002){ref-type="table-fn"}                                         Male                    1,566                  (28.2)     1,566    (28.2)
  Female                                                                                3,996                   (71.8)                 3,996      (71.8)   
  **Age**[^a^](#t001fn002){ref-type="table-fn"}                                         Mean \[SD\]             73.3                   \[6.9\]    73.3     \[6.9\]
  65--\<75 years                                                                        2,812                   (50.6)                 2,812      (50.6)   
  ≥75 years                                                                             2,750                   (49.4)                 2,750      (49.4)   
  **CCI score**[^b^](#t001fn003){ref-type="table-fn"}                                   Mean \[SD\]             3.65                   \[2.24\]   1.51     \[1.86\]
  **CCI diseases**[^b^](#t001fn003){ref-type="table-fn"}                                Myocardial infarction   107                    (1.9)      58       (1.0)
  Congestive heart failure                                                              572                     (10.3)                 322        (5.8)    
  Peripheral vascular disease                                                           1,492                   (26.8)                 831        (14.9)   
  Cerebrovascular disease                                                               2,110                   (37.9)                 591        (10.6)   
  Dementia                                                                              5,562                   (100.0)                0          (0.0)    
  Chronic obstructive pulmonary disease                                                 2,025                   (36.4)                 1,500      (27.0)   
  Connective tissue disease                                                             351                     (6.3)                  184        (3.3)    
  Peptic ulcer disease                                                                  1,863                   (33.5)                 1,272      (22.9)   
  Chronic liver disease                                                                 1,274                   (22.9)                 792        (14.2)   
  Diabetes mellitus (uncomplicated)                                                     1,559                   (28.0)                 978        (17.6)   
  Diabetes mellitus (complicated)                                                       664                     (11.9)                 394        (7.1)    
  Hemiplegia                                                                            234                     (4.2)                  43         (0.8)    
  Moderate/severe kidney disease                                                        94                      (1.7)                  58         (1.0)    
  Tumor, leukemia, lymphoma                                                             522                     (9.4)                  319        (5.7)    
  Moderate/severe liver disease                                                         27                      (0.5)                  12         (0.2)    
  Metastatic solid tumor                                                                46                      (0.8)                  32         (0.6)    
  Acquired immune deficiency syndrome                                                   1                       (0.0)                  0          (0.0)    
  **Other comorbidities related with dementia**[^b^](#t001fn003){ref-type="table-fn"}   Hypertension            3,702                  (66.6)     2,702    (48.6)
  Depression                                                                            959                     (17.2)                 326        (5.9)    
  Delirium                                                                              67                      (1.2)                  4          (0.1)    
  Behavior disorders due to alcohol                                                     43                      (0.8)                  11         (0.2)    
  Schizophrenia/psychotic disorders                                                     108                     (1.9)                  8          (0.1)    
  All other mental disorders                                                            2,500                   (44.9)                 1,309      (23.5)   
  **Average number of drugs**[^c^](#t001fn004){ref-type="table-fn"}                     Mean \[SD\]             2.54                   \[2.87\]   1.75     \[2.39\]

CCI: Charlson comorbidity index, DM: diabetes mellitus, SD: standard deviation.

^a^ The case and control groups had same distribution for age and sex due to matching.

^b^ CCI score, CCI disease, and other comorbidities were analyzed for the look-back period (0--2 years prior to the index date).

^c^ The number of average prescribed daily drugs were estimated by adding all drugs prescription days in the look-back period and dividing the sum by 730.

The prevalence of polypharmacy was 1.7-times more in cases; polypharmacy was observed in 18.8% of the cases and in 10.8% of the controls ([Fig 2](#pone.0169463.g002){ref-type="fig"}).

![Prevalence of polypharmacy in cases and controls.](pone.0169463.g002){#pone.0169463.g002}

The OR of a PIM prescription was 1.5--2.0 in the cases, indicating that the cases had a significantly higher exposure to PIMs than controls. The univariate OR for dementia increased with longer duration of PIM use (number of PIM prescription days) ([Table 2](#pone.0169463.t002){ref-type="table"}).

10.1371/journal.pone.0169463.t002

###### Exposure to dementia and cognitive impairment-related potentially inappropriate medications in cases and controls.

![](pone.0169463.t002){#pone.0169463.t002g}

  PIM                                                 MPR[^a^](#t002fn002){ref-type="table-fn"}   Cases (n = 5,562)   Controls (n = 5,562)   OR (95% CI)   MPR[^a^](#t002fn002){ref-type="table-fn"}   Cases (n = 5,562)   Controls (n = 5,562)   OR (95% CI)
  --------------------------------------------------- ------------------------------------------- ------------------- ---------------------- ------------- ------------------------------------------- ------------------- ---------------------- -------------
  **Benzodiazepine (all)**                            0                                           2,880 (52)          3,562 (64)             1             0                                           2,880 (52)          3,562 (64)             1
  \>0--100                                            2,682 (48)                                  2,000 (36)          1.73 (1.60--1.88)      \>0--\<50     2,325 (42)                                  1,854 (33)          1.63 (1.50--177)       
  50--100                                             357 (6)                                     146 (3)             3.16 (2.58--3.86)                                                                                                           
  **Benzodiazepine (short or intermediate acting)**   0                                           3,842 (69)          4,402 (79)             1             0                                           3,842 (69)          4,402 (79)             1
  \>0--100                                            1,720 (31)                                  1,160 (21)          1.77 (1.62--1.94)      \>0--\<50     1,524 (27)                                  1,066 (19)          1.71 (1.55--1.88)      
  50--100                                             196 (4)                                     94 (2)              2.46 (1.91--3.16)                                                                                                           
  **Benzodiazepine (long acting)**                    0                                           3,849 (69)          4,284 (77)             1             0                                           3,849 (69)          4,284 (77)             1
  \>0--100                                            1,713 (31)                                  1,278 (23)          1.51 (1.39--1.65)      \>0--\<50     1,604 (29)                                  1,233 (22)          1.47 (1.35--1.60)      
  50--100                                             109 (2)                                     45 (1)              2.75 (1.94--3.90)                                                                                                           
  **Benzodiazepine (receptor agonist)**               0                                           5,023 (90)          5,277 (95)             1             0                                           5,023 (90)          5,277 (95)             1
  \>0--100                                            539 (10)                                    285 (5)             2.00 (1.72--2.33)      \>0--\<50     504 (9)                                     271 (5)             1.97 (1.69--2.30)      
  50--100                                             35 (1)                                      14 (0)              2.66 (1.43--5.00)                                                                                                           
  **Anticholinergic drugs**                           0                                           2,445 (44)          3,140 (57)             1             0                                           2,445 (44)          3,140 (57)             1
  \>0--100                                            3,117 (56)                                  2,422 (44)          1.77 (1.63--1.92)      \>0--\<50     2,903 (52)                                  2,309 (42)          1.73 (1.59--1.87)      
  50--100                                             214 (4)                                     113 (2)             2.63 (2.07--3.35)                                                                                                           
  **H2-receptor antagonist**                          0                                           2,381 (43)          2,964 (53)             1             0                                           2,381 (43)          2,964 (53)             1
  \>0--100                                            3,181 (57)                                  2,598 (47)          1.66 (1.52--1.80)      \>0--\<50     2,959 (53)                                  2,472 (44)          1.62 (1.49--1.76)      
  50--100                                             222 (4)                                     126 (2)             2.47 (1.96--1.76)                                                                                                           

PIM: potentially inappropriate medication, OR: odds ratio, CI: confidence interval.

^a^ MPR: medication procession ratio, MPR was defined as the percentage of prescription days for the 2-year look-back period.

Univariate logistic regression analysis revealed that polypharmacy was associated with higher OR for dementia. The ORs for dementia increased significantly with the increasing number of prescribed drugs (1--\<5 drugs: 1.72, 95% CI: 1.56--1.88; 5--\<10 drugs: 2.64, 95% CI: 2.32--3.05; and ≥10 drugs: 3.35, 95% CI 2.38--4.71; \<1 drug used as reference). This trend for an increase in dementia OR with an increase in the number of prescribed drugs was stronger for other cause dementia than for Alzheimer's disease dementia. The integrated OR for the subgroup of patients with no specific comorbidities was 2.61 (95% CI: 2.51--2.72) for 5--\<10 used drugs, with the \<1 drug group used as a reference. However, the integrated OR was lower for the subgroup of patients with a specific comorbidity: 1.21 (1.07--1.38) for 5--\<10 used drugs ([Table 3](#pone.0169463.t003){ref-type="table"}). The individual ORs for comorbidity-based patient subgroups were higher in the subgroup with no specific comorbidity than in the subgroup where comorbidities were present ([S3 Table](#pone.0169463.s003){ref-type="supplementary-material"}).

10.1371/journal.pone.0169463.t003

###### Univariate logistic regression analysis for polypharmacy and dementia segregated by patient subgroups.

![](pone.0169463.t003){#pone.0169463.t003g}

  Average number of prescribed daily drugs   Crude OR (95% CI)   Integrated ORs[^d^](#t003fn005){ref-type="table-fn"} for subgroups with no specific comorbidities   Integrated ORs[^d^](#t003fn005){ref-type="table-fn"} for subgroups with specific comorbidities                                 
  ------------------------------------------ ------------------- --------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ -------------- -------------- ------
  **\<1**                                    1                   1                                                                                                   1                                                                                                1              1              1
  **1--\<5**                                 1.72                1.44                                                                                                2.31                                                                                             1.49           1.73           0.91
  (1.56--1.88)                               (1.23--1.68)        (1.97--2.72)                                                                                        (1.26--1.77)                                                                                     (1.68--1.77)   (0.82--1.02)   
  **5--\<10**                                2.64                2.14                                                                                                3.93                                                                                             1.99           2.61           1.21
  (2.32--3.05)                               (1.72--2.66)        (3.17--4.88)                                                                                        (1.54--2.57)                                                                                     (2.51--2.72)   (1.07--1.38)   
  **≥10**                                    3.35                2.24                                                                                                5.66                                                                                             2.92           3.22           1.49
  (2.38--4.71)                               (1.30--3.86)        (3.32--9.66)                                                                                        (1.33--6.44)                                                                                     (2.86--3.63)   (1.16--1.92)   

OR: odds ratio, CI: confidence interval.

^a^ Alzheimer's disease dementia: patients with ICD-10 codes F00, and G30, without F01, F02, F03, F051, and G311.

^b^ Other cause dementia: patients with ICD-10 codes of F01, F02, F03, F051, G311, without F00 and G30.

^c^ Mixed dementia: patients with Alzheimer's codes (F00 or G30) and any other cause dementia codes (F01, F02, F03, F051, G311) simultaneously.

^d^ The results were calculated by integrating ORs from results of all individual comorbidity status-based subgroups. Refer to [S3 Table](#pone.0169463.s003){ref-type="supplementary-material"} for the individual univariate ORs for each subgroup.

PIMs that exhibited significant interactions with polypharmacy were anticholinergics and H2-receptor antagonists (p\<0.0001, [S4 Table](#pone.0169463.s004){ref-type="supplementary-material"}). Among comorbidities, hypertension, peripheral or cerebrovascular disease, congestive heart failure, hemiplegia, diabetes, depression, all other mental disorders, chronic obstructive pulmonary disease, peptic ulcer disease, and chronic liver disease showed significant interactions with polypharmacy (p\<0.001, [S4 Table](#pone.0169463.s004){ref-type="supplementary-material"}).

We also compared ORs for dementia according to the interactions between comorbidities, PIMs, and polypharmacy. When not considering the interaction terms, the adjusted ORs increased significantly with the increasing levels of polypharmacy even as PIMs or the group of non-interacting diseases were included as variables. However, the magnitude of increase in ORs diminished when the group of interacting diseases was included in the analysis. When interaction terms were included in the analysis, the ORs for dementia in the polypharmacy group exhibited stronger increases in the absence of interacting PIMs or comorbidities but decreased and lost statistical significance when polypharmacy-interacting drugs or diseases were present ([Table 4](#pone.0169463.t004){ref-type="table"}).

10.1371/journal.pone.0169463.t004

###### Multivariable logistic regression analysis with or without interaction terms.

![](pone.0169463.t004){#pone.0169463.t004g}

  Variables                                                                          OR (95% CI) for dementia                                                                                                                                        
  ---------------------------------------------------------------------------------- -------------------------- -------------- -------------- ------------------------------------------- -------------- ------------------------------------------- ----------
  **\<1**[^a^](#t004fn002){ref-type="table-fn"}                                      1                          1              1              1                                           1              1                                           1
  **1--\<5**[^a^](#t004fn002){ref-type="table-fn"}                                   1.39                       1.34           0.86           1.98                                        1.20           3.01                                        0.83
  (1.25--1.53)                                                                       (1.21--1.48)               (0.77--0.96)   (1.63--2.40)   (1.07--1.34)                                (1.68--5.40)   (0.74--0.93)                                
  **5--\<10**[^a^](#t004fn002){ref-type="table-fn"}                                  1.92                       1.81           1.17           2.58                                        1.70           \- [^e^](#t004fn006){ref-type="table-fn"}   1.15
  (1.67--2.21)                                                                       (1.57--2.08)               (1.01--1.36)   (1.75--3.81)   (1.46--1.99)                                (0.99--1.34)                                               
  **≥10**[^a^](#t004fn002){ref-type="table-fn"}                                      2.23                       2.11           1.43           \- [^e^](#t004fn006){ref-type="table-fn"}   2.10           \- [^e^](#t004fn006){ref-type="table-fn"}   1.40
  (1.57--3.18)                                                                       (1.48--3.01)               (1.00--2.05)   (1.47--3.00)   (0.97--2.01)                                                                                           
  **Benzodiazepine (short/intermediate-acting)**                                     1.27                       1.24           1.17           1.29                                        1.29           1.18                                        1.18
  (1.15--1.41)                                                                       (1.12--1.37)               (1.05--1.30)   (1.17--1.43)   (1.17--1.43)                                (1.06--1.31)   (1.06--1.31)                                
  **Benzodiazepine (long-acting)**                                                   1.08                       1.06           1.03           1.11                                        1.11           1.04                                        1.04
  (0.98--1.19)                                                                       (0.96--1.16)               (0.93--1.14)   (1.01--1.21)   (1.01--1.21)                                (0.94--1.15)   (0.94--1.15)                                
  **Benzodiazepine (receptor agonist)**                                              1.45                       1.44           1.38           1.44                                        1.44           1.39                                        1.39
  (1.23--1.70)                                                                       (1.23--1.69)               (1.17--1.63)   (1.23--1.67)   (1.23--1.67)                                (1.18--1.64)   (1.18--1.64)                                
  **Anticholinergic drugs**[^b^](#t004fn003){ref-type="table-fn"}                    1.29                       1.28           1.09           absence                                     presence       1.09                                        1.09
  (1.18--1.42)                                                                       (1.17--1.41)               (0.99--1.21)   (0.98--1.20)   (0.98--1.20)                                                                                           
  **H2-receptor antagonists**[^b^](#t004fn003){ref-type="table-fn"}                  1.17                       1.16           0.95           absence                                     presence       0.95                                        0.95
  (1.07--1.29)                                                                       (1.05--1.28)               (0.86--1.06)   (0.85--1.05)   (0.85--1.05)                                                                                           
  **Group of non-interacting comorbidities**[^c^](#t004fn004){ref-type="table-fn"}   \-                         1.87           1.68           \-                                          \-             1.69                                        1.69
  (1.67--2.10)                                                                       (1.49--1.89)               (1.50--1.90)   (1.50--1.90)                                                                                                          
  **Group of interacting comorbidities**[^d^](#t004fn005){ref-type="table-fn"}       \-                         \-             6.53           \-                                          \-             absence                                     presence
  (5.37--7.29)                                                                                                                                                                                                                                       

OR: odds ratio, CI: confidence interval.

^a^ the number of average prescribed daily drugs analyzed for the 2-year look-back period.

^b^ polypharmacy interacting drugs: anticholinergic drugs and H2-receptor antagonists.

^c^ group of comorbidities showing non-significant interaction: concomitant diseases which did not show significant interaction with polypharmacy.

^d^ polypharmacy interacting comorbidities: concomitant diseases that showed significant interactions such as hypertension, peripheral or cerebrovascular disease, congestive heart failure, hemiplegia, diabetes, depression, all other mental disorders, chronic obstructive pulmonary disease, peptic ulcer disease, and chronic liver disease.

^e^ not analyzed due to limited sample size (n\<5).

Discussion {#sec011}
==========

We conducted a nested case-control study using a 12-year longitudinal cohort database representing the overall South Korean population, and our results confirm the association between polypharmacy and dementia. In a previous study, Lai *et al*. compared polypharmacy status among elderly people with and without dementia using the National Health Insurance data in Taiwan \[[@pone.0169463.ref020]\]. Their results showed that the risk of dementia increased with medication use, and confirmed that cerebrovascular disease interacted with polypharmacy. In comparison to the study by Lai *et al*., we excluded all hospitalized patients and only included outpatients to focus on the newly diagnosed dementia cases. Additionally, in our study, we matched the cases and controls for age and sex, which are major confounding factors for dementia. Furthermore, we used sophisticated analysis methods such as adjustment for PIM, and multiple logistic regression analyses that included interactions between polypharmacy and comorbidities or PIM to obtain more robust data on the association between polypharmacy and dementia.

A previous study by Draper *et al*. noted that approximately 25% dementia patients were hospitalized and that the average length of hospital stay for dementia patients was nearly double that of the non-dementia patients (16.5 days versus 8.9 days). They further reported that dementia was identified as the principal reason for hospitalization in only 6% of the cases \[[@pone.0169463.ref024]\]. In another study conducted in South Korea to assess the number of daily prescription drugs administered, the average number of daily prescribed drugs was 10% higher in the case group that included inpatients compared to the group that consisted only of outpatients \[[@pone.0169463.ref025]\]. Therefore, the exclusion of subjects with prior hospitalization history in this study is a conservative approach that lowers the possibility of including serious comorbidities among the newly diagnosed dementia cases.

We recorded a maximum of five comorbidities or CCI diseases for each patient, and these diseases are likely to be correlated to one another. Thus, a subgroup with a specific comorbidity could have other comorbidities simultaneously. Therefore, multicollinearity may be a concern when assessing comorbidities which have high correlation in one model. Various statistical methods have been recommended to overcome multicollinearity \[[@pone.0169463.ref026]\]. In this study, we used two approaches; firstly, we integrated the results from univariate logistic regression analyses conducted on patient subgroups with and without individual comorbidities. Secondly, based on their association with polypharmacy, we divided the comorbidities into interacting and non-interacting groups and conducted multiple logistic regression analyses to compare the results obtained by including and excluding the interaction terms. The association between polypharmacy and dementia remained statistically significant even after adjusting for comorbidities and PIM use even though the magnitude of the association decreased compared to the unadjusted values. It should be noted that the results of the association analysis depend on the statistical methods used.

There are several explanations for the association between polypharmacy and dementia. Polypharmacy may lead to a higher risk of dementia-related PIM use, and this may occur irrespective of whether or not the PIM is identified. The Beers criteria identify anticholinergic drugs, benzodiazepines, and H2-receptor antagonists as established PIMs for dementia due to their adverse effects on the central nervous system \[[@pone.0169463.ref023], [@pone.0169463.ref027]--[@pone.0169463.ref030]\]. As shown in [Table 2](#pone.0169463.t002){ref-type="table"}, higher exposure to these PIMs was associated with higher risk of dementia. Thus, these PIMs should only be prescribed when essential, and prolonged use among the elderly should be avoided. In addition to the established PIMs listed in the Beers criteria, numerous other PIMs (such as proton pump inhibitors, antipsychotics, antidepressants, and opioids) may also be associated with dementia; however, the mechanisms for these associations are not yet clear \[[@pone.0169463.ref028], [@pone.0169463.ref031], [@pone.0169463.ref032]\]. Although it is generally known that established PIMs worsen dementia, there remain controversies on PIM use and the risk of developing dementia. A previous study reported a case of dementia that was reversed following the withdrawal of some prescribed drugs, and the authors emphasized the grave implications of polypharmacy on multiple comorbidities in dementia patients \[[@pone.0169463.ref033], [@pone.0169463.ref034]\]. Studies indicate that properly managed polypharmacy may help prevent, or delay, the development of dementia; however, further work is needed to verify this.

Additionally, the use of PIMs may cause continuous cognitive impairment. Dementia refers to a complex clinical syndrome that includes cognitive impairment and a decline in mental skills such as learning, language, and intelligence. This can be due to various causes and results in various functional impairments \[[@pone.0169463.ref035]\]. Wolkowitz *et al*. reported that following long-term steroid use, patients may develop prominent and persistent cognitive impairments due to drug-related neurotoxicity \[[@pone.0169463.ref036], [@pone.0169463.ref037]\]. Several experimental studies have been conducted to assess the impact of polypharmacy on cognitive function; however, the study results remain controversial. Jykka *et al*. assessed cognitive capacity using the Mini-Mental Status Examination (MMSE) scores, and compared them based on the polypharmacy levels. They noted that cases with excessive polypharmacy (≥10 drugs) exhibited significantly decreased cognitive function compared to non-polypharmacy cases (0--5 drugs) \[[@pone.0169463.ref038]\]. However, other studies reported a lack of association between polypharmacy and cognitive impairment in men \[[@pone.0169463.ref012], [@pone.0169463.ref039]\]. Wang *et al*. measured the cognitive capacity of hospitalized men aged ≥80 years using the MMSE, and also reported a lack of correlation between the scores and polypharmacy \[[@pone.0169463.ref012]\]. In both studies, polypharmacy level was analyzed with respect to cognitive test scores, and not dementia diagnosis. As MMSE is only one component of the assessments made to reach a diagnosis of dementia, the scores may not exactly correlate with the diagnosis, as noted by Brown *et al*. \[[@pone.0169463.ref040]\]. Moreover, constant exposure to polypharmacy can result in cognitive impairment, that may, in long-term, develop into dementia.

In addition to polypharmacy, comorbidities also exhibited a strong influence on dementia. The cases in our study had a higher prevalence of comorbidities than the controls even before a dementia diagnosis. A previous study has noted the association between hypertension and dementia \[[@pone.0169463.ref041]\]. Similarly, in this study, we observed a significantly higher prevalence of hypertension in the cases (67% versus 49% in the controls) during the look-back period. In the subgroups of patients with specific comorbidities, the crude OR for dementia decreased and lost statistical significance, and the lowest OR for dementia was observed in the subgroup of patients with concomitant cerebrovascular diseases (the OR for 5--\<10 used drugs was 0.61 with 95% CI of 0.33--1.10, with the \<1 drug used as reference) ([S3 Table](#pone.0169463.s003){ref-type="supplementary-material"}). In a multiple regression analysis, similarly, the adjusted OR for dementia decreased in the presence of comorbidity ([Table 4](#pone.0169463.t004){ref-type="table"}). Therefore, in our study population, comorbidity was directly associated with dementia and was also the primary reason for an increase in the number of drugs prescribed. These results highlight the need for the careful management of comorbidities to prevent dementia.

In this study, as an exploratory analysis, we also assessed the impact of polypharmacy on the three dementia types. We observed that the diagnosis of non-Alzheimer's dementia was most strongly affected by the level of polypharmacy. We defined non-Alzheimer's dementia as a diagnosis with no Alzheimer-specific ICD-10 codes, and vascular disease dementia was considered to be the major subtype of non-Alzheimer's dementia. Based on a nationwide survey in Korea, the proportion of non-Alzheimer dementia cases was 28.2%; our results exhibited slightly higher proportion. The proportion of vascular dementia cases was 82% of all the non-Alzheimer types, Lewy body dementia, Parkinson's disease with dementia, frontotemporal dementia, and alcohol-related dementia accounted for only 2--3%; and not specified dementia accounted for 9% of all the non-Alzheimer types \[[@pone.0169463.ref042]\]. Kim *et al*. compared the comorbidity status of community-dwelling dementia patients based on the types of dementia and reported that the total comorbidity score was significantly higher in vascular disease dementia than in Alzheimer's disease dementia (7.49±3.53 versus 5.46±3.13, p\<0.001) \[[@pone.0169463.ref043]\]. As noted above, non-Alzheimer's dementia includes various subgroups; however, we could not analyze the effect of polypharmacy levels on these subtypes because the records of subtypes were frequently missed in the database. Comorbidity could be the main risk factor for polypharmacy and dementia based on Kim's studies; however, further analysis should be followed to determine how polypharmacy independently affects the development of a specific dementia subtype.

Our results demonstrate the relationship between polypharmacy and dementia, highlighting the need for multilateral efforts to reduce polypharmacy among the elderly. Several other reasons necessitate the control of polypharmacy. First, excessive polypharmacy results in a higher risk of PIM administration \[[@pone.0169463.ref019], [@pone.0169463.ref044]--[@pone.0169463.ref047]\]. A survey showed that about 50% of the community-dwelling patients with Alzheimer's disease received PIMs, and such medications were even prescribed by Alzheimer specialists \[[@pone.0169463.ref048]\]. Second, polypharmacy may be related to functional decline \[[@pone.0169463.ref049]\], and a decreased quality of life among elderly dementia patients \[[@pone.0169463.ref050]\]. In a Japanese study based on elderly people with dementia who recently started receiving community-dwelling care, the quality of life and score of daily living activities were compared for 6 months between the reduced medication number (intervention) group and non-intervention group. Intervention group maintained their quality of life even as the medication number decreased during 6 months and showed slightly, however significantly, greater scores of daily living activities group compared to non-intervention group \[[@pone.0169463.ref050]\]. Third, polypharmacy could increase mortality risks in limited life expectancy groups. A study showed that polypharmacy was related with an increased mortality risk for the end-staged patients with advanced cognitive impairment in nursing homes; therefore, risks and benefits of polypharmacy should be evaluated, and the drug regimen should be improved to be as simple as possible for those patients \[[@pone.0169463.ref051]\]. Lastly, pill burden should be considered in addition to the risks associated with polypharmacy. We defined the level of polypharmacy based on the total number of either the type of drugs or the active ingredients in the drugs; therefore, the actual number of pills may be a few folds higher. Furthermore, it must be noted that some patients have difficulties in swallowing functions and taking multiple pills daily could affect adherence to the prescribed medication and treatment outcomes \[[@pone.0169463.ref052]\].

It may not be possible to completely avoid PIMs or exercise adequate caution in the administration of PIMs that negatively affect dementia as their mechanisms of action and impacts are diverse, and even undetermined in some cases. Therefore, practically, prescribing only the essential drugs would be the safest option for elderly dementia patients, and prescribing physicians should try to avoid increasing the number of medications \[[@pone.0169463.ref013], [@pone.0169463.ref053]\]. The need for deprescription has been recognized widely; however, policy measures to manage polypharmacy should be more actively implemented and executed with the increase in the elderly population and in the rising incidence of dementia. In addition, the causal relationship between polypharmacy and dementia, and the risks associated with the drugs used for treating dementia should be studied in the future.

This study is limited in its generalizability to other populations as all study subjects were Korean, and the database had limited information on patients' clinical and laboratory data. For instance, previous studies have reported the association between body mass index (BMI) and the incidence of dementia \[[@pone.0169463.ref054], [@pone.0169463.ref055]\], and Koreans generally tend to have lower BMI than westerners. Based on the national health and nutrition examination surveys conducted in Korea and in the United States, the average BMI among the elderly population was 23.8 kg/m^2^ (SD: 3.2) in Korea \[[@pone.0169463.ref056]\], and 28.3 kg/m^2^ (SD: 7.1) in the United States \[[@pone.0169463.ref057]\]. Other limitations of this study are similar to those studies, which utilized reimbursement claim data for analysis \[[@pone.0169463.ref025]\]. The data on the number of drugs used is based solely on prescriptions, and the actual administration may be different. Moreover, over-the-counter, complementary, and alternative medications were not included in the list of administered/prescribed drugs. Additionally, PIM exposure did not include information on the level of drug use, such as the dosage of the administered drugs. Our study utilized information from insurance claims database, and, therefore, we could not access the patients' medical records. We classified cases based on the ICD-10 codes included in the database, and although the diagnoses were recorded by health care professionals, there remains the possibility of misclassification or misdiagnosis. Polypharmacy showed a stronger association with vascular dementia than with Alzheimer's disease dementia; however, the risk of misdiagnosis may be larger for the subtypes of dementia. Our evaluation of the association between polypharmacy and individual dementia subtypes were thus limited, and future studies should elucidate these associations further, utilizing well-defined case selection and study design.

This study has several strengths. The use of multiple statistical approaches and the utilization of long-term cohort data from real world setting, representative of the entire South Korean population provides robustness to our results and strongly emphasizes the association between polypharmacy and dementia.

In conclusion, polypharmacy was significantly associated with the incidence of dementia even after the association was adjusted for dementia-related PIM use. Additional efforts are needed to maintain or reduce the number of prescribed drugs in order to reduce the risk of dementia.
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###### The ICD-10 codes used for analysis.

(DOCX)

###### 

Click here for additional data file.

###### Demographics and clinical information for the dementia type-based subgroups.

SD: standard deviation, CCI: Charlson comorbidity index.

^a^ Alzheimer's disease dementia: patients with ICD-10 codes F00 and G30, without F01, F02, F03, F051, and G311.

^b^ Other cause dementia: patients with ICD-10 codes F01, F02, F03, F051, and G311, without F00 and G30.

^c^ Mixed dementia: patients with Alzheimer's codes (F00 or G30) and any other cause dementia codes (F01, F02, F03, F051, and G311) simultaneously.

^d^ D1: myocardial infarction, D2: congestive heart failure, D3: peripheral vascular disease, D4: cerebrovascular vascular disease, D5: dementia, D6: chronic obstructive pulmonary disease, D7: connective tissue disease, D8: peptic ulcer disease, D9: chronic liver disease, D10: diabetes mellitus (uncomplicated), D11: diabetes mellitus (complicated), D12: Hemiplegia, D13: moderate/severe kidney disease, D14: tumor, leukemia, lymphoma, D15: moderate/severe liver disease, D16: metastatic solid tumor, D17: acquired immune deficiency syndrome, D18: hypertension, D19: depression, D20: delirium, D21: behavioral disorders due to alcohol, D22: schizophrenia/psychotic disorders, D23: all other mental disorders.

(DOCX)

###### 

Click here for additional data file.

###### The results of univariate logistic regression analyses according to patient comorbidity subgroup.

OR: odds ratio, CI: confidence interval, PIM: potentially inappropriate medication, NA: not applicable.

^a^ Data not available due to the small size for matched controls.

(DOCX)

###### 

Click here for additional data file.

###### Interaction between polypharmacy and predictor variables.

(DOCX)

###### 

Click here for additional data file.
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